• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ACADIA Pharmaceuticals downgraded by Guggenheim with a new price target

    1/3/25 7:17:06 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACAD alert in real time by email
    Guggenheim downgraded ACADIA Pharmaceuticals from Buy to Neutral and set a new price target of $20.00 from $23.00 previously
    Get the next $ACAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACAD

    DatePrice TargetRatingAnalyst
    5/21/2025$35.00Hold → Buy
    Deutsche Bank
    2/11/2025$22.00Hold
    Deutsche Bank
    1/3/2025$23.00 → $20.00Buy → Neutral
    Guggenheim
    10/10/2024Mkt Perform
    Raymond James
    8/7/2024$28.00 → $20.00Overweight → Equal-Weight
    Morgan Stanley
    6/27/2024$31.00Outperform
    BMO Capital Markets
    3/12/2024$36.00 → $32.00Buy
    Needham
    3/12/2024$39.00 → $25.00Buy → Neutral
    Mizuho
    More analyst ratings

    $ACAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Brege Laura sold $314,634 worth of shares (14,446 units at $21.78), decreasing direct ownership by 49% to 15,095 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      6/5/25 6:01:14 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Daly James M converted options into 9,387 shares, increasing direct ownership by 38% to 34,041 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      6/2/25 6:05:06 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ndu Adora converted options into 9,387 shares, increasing direct ownership by 61% to 24,801 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      6/2/25 6:05:12 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care